Nonmetastatic CRPC: Treatment Selection
An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.
Advances in Nonmetastatic CRPC
An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.
Oral GnRH Antagonist Therapy for mCSPC
Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.
mCSPC: Applying New Data into Clinical Practice
Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.
Triple Therapy Approaches for mCSPC
Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.
ADT Monotherapy in mCSPC
The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.
Treatment Advances in mCSPC
18F-DCFPyL PET/CT Imaging for Suspected Recurrent Prostate Cancer
A discussion regarding use of the PSMA-targeted 18F-DCFPyL PET/CT to assess patients with suspected recurrence of prostate cancer based on data revealed by the CONDOR trial.
PSMA-Targeted 18F-DCFPyL PET/CT in High-Risk Prostate Cancer
An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.
Phenotypic Biomarkers in Advanced Prostate Cancer
A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.
Tissue and Liquid Biopsies in Advanced Prostate Cancer
Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.
Precision Medicine in Advanced Prostate Cancer
A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.